Abstract
P-glycoprotein (P-gp), a cellular drug-efflux pump is thought to be one of the major causes of multidrug resistance in malignancies. Since therapeutic strategies are being developed to circumvent drug resistance by inhibiting P-gp, prospective studies concerning the clinical relevance of P-gp in childhood leukemia are warranted. Methods: P-gp was studied in 102 consecutive cases of de novo childhood ALL and in 34 relapsed patients. An immunocytochemical technique with two monoclonal antibodies (C219,4E3) was used on bone marrow and blood smears. Results: 12/34 (35%) children were scored positive at relapse compared to 12/102 (12%) children with newly diagnosed ALL (p =0.006). No correlation between P-gp expression and clinical and hematological parameters was seen. All patients were treated according to the EORTC-CLCG protocols (survival at 5 years=85%). 20/102 patients relapsed. The mortality rate in the P-gp positive group was significantly worse (Logrank P=0.009) than in the P-gp negative patients. In the relapsed patient population 10/12 P-gp positive cases experienced an unfavourable outcome compared with 10/22 P-gp negative patients [Risk Ratio 2.21 (0.90–5.45)]. Conclusions: P-glycoprotein expression in newly diagnosed childhood ALL is an independent prognostic parameter for dismal outcome. P-gp positivity at relapse tends towards an adverse clinical outcome compared to the P-gp negative relapsed population
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Kartner N, Ling V (1989) Multidrug Resistance in Cancer. Scientific American 26–33
Carulli G, Petrini M, Marini A, Ambrogi F (1988) P-glycoprotein in acute leukemia and in the blastic crisis of myeloid leukemia. N Engl J Med 319:797–798
Kuwazuru Y, Yoshimura A, Hanada S, Utsunomiya A, Makino T, Ishibashi K, Kodama M, Iwahashi M, Arima T, Akiyama S (1990) Expression of the Multidrug transporter, P-Glycoprotein, in Acute Leukemia Cells and Correlation to Clinical Drug Resistance. Cancer 66:868–873
Wattel E, Lepelley P, Merlat A (1995) Expression of the multidrug resistance P glycoprotein in newly diagnosed adult acute lymphoblastic leukemia: absence of correlation with response to treatment. Leukemia 9:1870–1874
Mizuno Y, Hara T, Nagata M, Tawa A, Tsuruo T, Ueda K (1991) Detection of multidrug-resistant protein, P-glycoprotein in childhood leukaemia and lymphoma. Eur J Pediatr 150:416–418
Ubezio P, Limonta M, D’Incalci M, Damia G, Masera G, Giudici G, Wolverto J, Beck WT (1989) Failure to detect the P-glycoprotein multidrug resistant phenotype in case of resistant childhood acute lymphoblastic leukemia. Eur J Cancer Clin Oncol 25:1895–1899
Pieters R, Hongo T, Loonen AH (1992) Different types of non-P-glycoprotein mediated multiple drug resistance in children with relapsed acute lymphoblastic leukeamia. Br. J Cancer 65:691–697
Langermann H J, Henze G, Wulf M, Riehm H (1982) Abschatzung der Tumorzellmasse bei der akuten lymphoblastischen Leukamie im Kindersalter: prognostische Bedeutung und praktische Anwendung. Klin. Pediatr. 194:209–213
Kartner N, Evernden-Porelle D, Bradley G, Ling V (1985) Detection of P-glycoprotein in multidrug-resistant cell lines by monoclonal antibodies. Nature 316:820–823
Cordell JL, Falini B, Erber WN (1984) Immunoenzymatic labeling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal anti-alkaline phosphatase (APAAP) complexes. J Histochem Cytochem 32:219–229
C Dhooge, De Moerloose B., De Potter C. (1994) Expression of the Multidrug Transporter, P-Glycoprotein, in Childhood Leukemia:A Prospective Clinical Study. International Journal of Pediatric Hematology/Oncology (1):311–314
Beck WT, Grogan TM, Willman CL (1996) Methods to detect P-Glycoprotein-associated Multidrug Resistance in Patients ‘Tumors: Consensus Recommendations. Cancer Research 56:3010–3020
Knaust E, MacDonald P, Gruber A (1998) Heterogeneity in blast cell populations in acute myeloid leukemia (AML) affects accumulation abd efflux of daunorubicin. Leukemia 12.(2) 3rd Intern Symposium of Drug Resistance in Leukemia and Lymphoma:p10 (abstract)
List AF, Spier C, Greer J (1993) Phase I/II Trial of Cyclosporine as a Chemotherapy-Resistance Modifier in Acute Leukemia. Journal of Clinical Oncology 11(9): 1652–1660
Schlaifer D, Laurent G, Chittal S, Tsuruo T, Soues S, Muller C, Charcosset J Y, Alard C, Brousset P, Mazerrolles C, Delsol G (1990) Immunohistochemical detection of multidrug resistance associated P-glycoprotein in tumour and stromal cells of human cancers. Br J Cancer 62, 177–182
Rothenberg ML, Mickley LA, Cole DE, Balis FM, Tsuruo T, Poplack D, Fojo AT (1989) Expression of mdr1/ P-170 gene in patients with acute lymphoblastic leukemia. Blood 74:1388–1395
Pui C-H (1995) Childhood Leukemias. The new England Journal of Medicine 332(24): 1618–1630
Leith CP, Kopecky KJ, Godwin J (1997) Acute Myeloid Leukemia in the Elderly: Assessment of Multidrug Resistance (MDR1) and Cytogenetics Distinguishes Biologic Subgroups with Remarkably Distinct Responses to Standard Chemotherapy. A Southwest Oncology Group Study.Blood 89(9):3323–3329
Del Poeta G, Venditti A, Aronica G (1997) P-Glycoprotein expressiopn in de novo acute myeloid leukemia. Leukemia and Lymphoma 21:257–274
Van den Heuvel-Eibrinck M.M., van der Holt B, Te Boekhorst P.A.W. (1997) MDR1 expression is an independent prognostic factor for response and survival in de novo acute myeloid leukemia Br. J. Haem. 99:76–83
Van der Heyden S, Gheuens E, De Bruijn E (1995) P-Glycoprotein: Clinical Significance and Methods of Analysis. Critical reviews in Clinical Laboratory Sciences 32(3):221–264
Chan HSL, Thorner PS, Haddad G (1995) Multidrug resistance in Malignancies of Children. International Journal of Pediatric Hematology/Oncology 2:11–29
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1999 Springer Science+Business Media New York
About this chapter
Cite this chapter
Dhooge, C., De Moerloose, B. (1999). Clinical Significance of P-Glycoprotein (P-gp) Expression in Childhood Acute Lymphoblastic Leukemia. In: Kaspers, G.J.L., Pieters, R., Veerman, A.J.P. (eds) Drug Resistance in Leukemia and Lymphoma III. Advances in Experimental Medicine and Biology, vol 457. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-4811-9_2
Download citation
DOI: https://doi.org/10.1007/978-1-4615-4811-9_2
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-7180-9
Online ISBN: 978-1-4615-4811-9
eBook Packages: Springer Book Archive